{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:56Z","timestamp":1794047456340,"version":"4.8.0"},"reference-count":51,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"6","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>REIIBP is a lysine methyltransferase aberrantly expressed through alternative promoter usage of NSD2 locus in t(4;14)-translocated multiple myeloma (MM). Clinically, t(4;14) translocation is an adverse prognostic factor found in approximately 15% of MM patients. The contribution of REIIBP relative to other NSD2 isoforms as a dependency gene in t(4;14)-translocated MM remains to be evaluated. Here, we demonstrated that despite homology with NSD2, REIIBP displayed distinct substrate specificity by preferentially catalyzing H3K4me3 and H3K27me3, with little activity on H3K36me2. Furthermore, REIIBP was regulated through microRNA by EZH2 in a Dicer-dependent manner, exemplifying a role of REIIBP in SET-mediated H3K27me3. Chromatin immunoprecipitation sequencing revealed chromatin remodeling characterized by changes in genome-wide and loci-specific occupancy of these opposing histone marks, allowing a bidirectional regulation of its target genes. Transcriptomics indicated that REIIBP induced a pro-inflammatory gene signature through upregulation of TLR7, which in turn led to B-cell receptor-independent activation of BTK and driving NFkB-mediated production of cytokines such as IL-6. Activation of this pathway is targetable using Ibrutinib and partially mitigated bortezomib resistance in a REIIBP xenograft model. Mechanistically, REIIBP upregulated TLR7 through eIF3E, and this relied on eIF3E RNA-binding function instead of its canonical protein synthesis activity, as demonstrated by direct binding to the 3\u2019UTR of TLR7 mRNA. Altogether, we provided a rationale that co-existence of different NSD2 isoforms induced diversified oncogenic programs that should be considered in the strategies for t(4;14)-targeted therapy.<\/jats:p>","DOI":"10.3324\/haematol.2023.283467","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T03:40:41Z","timestamp":1703130041000},"page":"1893-1908","source":"Crossref","is-referenced-by-count":2,"title":["Epigenetic dysregulation of eukaryotic initiation factor 3 subunit E (eIF3E) by lysine methyltransferase REIIBP confers a pro-inflammatory phenotype in t(4;14) myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Phyllis S.Y.","family":"Chong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing Yuan","family":"Chooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Lynn Julia","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Hoon","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhard","family":"Brunmeir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron Chung Yong","family":"Leow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina Hui Min","family":"Toh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalpnaa","family":"Balan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhamad Irfan Bin","family":"Azaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagavidya","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah A","family":"Vardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wee-Joo","family":"Chng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"62232","doi-asserted-by":"crossref","unstructured":"Palumbo A, Anderson K. Multiple myeloma. N Engl J Med. 201; 364(11):1046-1060.","DOI":"10.1056\/NEJMra1011442"},{"key":"62233","doi-asserted-by":"crossref","unstructured":"Lu S, Wang J. The resistance mechanisms of proteasome inhibitor bortezomib. Biomark Res. 2013; 1(1):13.","DOI":"10.1186\/2050-7771-1-13"},{"key":"62234","doi-asserted-by":"crossref","unstructured":"Quach H, Ritchie D, Stewart AK. Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma. Leukemia. 2010; 24(1):22-32.","DOI":"10.1038\/leu.2009.236"},{"key":"62235","unstructured":"Raedler LA. Darzalex (daratumumab): first anti-CD38 monoclonal antibody approved for patients with relapsed multiple myeloma. Am Health Drug Benefits. 2016; 9:70-73."},{"key":"62236","doi-asserted-by":"crossref","unstructured":"Fonseca R, Bergsagel PL, Drach J. International Myeloma Working Group molecular classification of multiple myeloma: spotlight review. Leukemia. 2009; 23(12):2210-2221.","DOI":"10.1038\/leu.2009.174"},{"key":"62237","doi-asserted-by":"crossref","unstructured":"Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol. 2007; 20(4):571-596.","DOI":"10.1016\/j.beha.2007.08.004"},{"key":"62238","doi-asserted-by":"crossref","unstructured":"Chng W, Dispenzieri A, Chim C. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014; 28(2):269-277.","DOI":"10.1038\/leu.2013.247"},{"key":"62239","doi-asserted-by":"crossref","unstructured":"Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7(8):585-598.","DOI":"10.1038\/nrc2189"},{"key":"62240","doi-asserted-by":"crossref","unstructured":"Keats JJ, Maxwell CA, Taylor BJ. Overexpression of transcripts originating from the NSD locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients. Blood. 2005; 105(10):4060-4069.","DOI":"10.1182\/blood-2004-09-3704"},{"key":"62241","doi-asserted-by":"crossref","unstructured":"Brito JL, Walker B, Jenner M. NSD deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009; 94(1):78-86.","DOI":"10.3324\/haematol.13426"},{"key":"62242","doi-asserted-by":"crossref","unstructured":"Kuo AJ, Cheung P, Chen K. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Mol Cell. 2011; 44(4):609-620.","DOI":"10.1016\/j.molcel.2011.08.042"},{"key":"62243","doi-asserted-by":"crossref","unstructured":"Pei H, Zhang L, Luo K. NSD regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites. Nature. 2011; 470(7332):124-128.","DOI":"10.1038\/nature09658"},{"key":"62244","doi-asserted-by":"crossref","unstructured":"Popovic R, Martinez-Garcia E, Giannopoulou EG. Histone methyltransferase NSD\/NSD2 alters EZH2 binding and reprograms the myeloma epigenome through global and focal changes in H3K36 and H3K27 methylation. PLoS Genet. 2014; 10(9):e1004566.","DOI":"10.1371\/journal.pgen.1004566"},{"key":"62245","doi-asserted-by":"crossref","unstructured":"Lhoumaud P, Badri S, Rodriguez-Hernaez J. NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains. Nat Commun. 2019; 10(1):4843.","DOI":"10.1038\/s41467-019-12811-4"},{"key":"62246","doi-asserted-by":"crossref","unstructured":"Martinez-Garcia E, Popovic R, Min D-J. The NSD histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells. Blood. 2011; 117(1):211-220.","DOI":"10.1182\/blood-2010-07-298349"},{"key":"62247","doi-asserted-by":"crossref","unstructured":"Lauring J, Abukhdeir AM, Konishi H. The multiple myeloma-associated NSD gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 2008; 111(2):856-864.","DOI":"10.1182\/blood-2007-05-088674"},{"key":"62248","doi-asserted-by":"crossref","unstructured":"Brito JLR, Walker B, Jenner M. NSD deregulation affects cell cycle progression and adhesion regulons in t(4;14) myeloma plasma cells. Haematologica. 2009; 94(1):78-86.","DOI":"10.3324\/haematol.13426"},{"key":"62249","doi-asserted-by":"crossref","unstructured":"Xie Z, Chooi JY, Toh SHM. NSD I acts as an oncoprotein and regulates GLO1 expression in t(4;14) multiple myeloma cells. Leukemia. 2019; 33(3):739-748.","DOI":"10.1038\/s41375-018-0300-0"},{"key":"62250","doi-asserted-by":"crossref","unstructured":"Garlisi CG, Uss AS, Xiao H. A unique mRNA initiated within a middle intron of WHSC1\/NSD encodes a DNA binding protein that suppresses human IL-5 transcription. Am J Respir Cell Mol Biol. 2001; 24(1):90-98.","DOI":"10.1165\/ajrcmb.24.1.4224"},{"key":"62251","doi-asserted-by":"crossref","unstructured":"Nishioka K, Chuikov S, Sarma K. Set9, a novel histone H3 methyltransferase that facilitates transcription by precluding histone tail modifications required for heterochromatin formation. Genes Dev. 2002; 16(4):479-489.","DOI":"10.1101\/gad.967202"},{"key":"62252","doi-asserted-by":"crossref","unstructured":"Chu L, Su MY, Maggi LB Jr. Multiple myeloma-associated chromosomal translocation activates orphan snoRNA ACA11 to suppress oxidative stress. J Clin Invest. 2012; 122(8):2793-2806.","DOI":"10.1172\/JCI63051"},{"key":"62253","doi-asserted-by":"crossref","unstructured":"Mirabella F, Wu P, Wardell CP. NSD is the key molecular target in t(4;14) myeloma. Blood Cancer J. 2013; 3(5):e114.","DOI":"10.1038\/bcj.2013.9"},{"key":"62254","doi-asserted-by":"crossref","unstructured":"Fingerman IM, Du HN, Briggs SD. In vitro histone methyltransferase assay. CSH Protoc. 2008; 2008:pdb.prot4939.","DOI":"10.1101\/pdb.prot4939"},{"key":"62255","doi-asserted-by":"crossref","unstructured":"Morey L, Helin K. Polycomb group protein-mediated repression of transcription. Trends Biochem Sci. 2010; 35(6):323-332.","DOI":"10.1016\/j.tibs.2010.02.009"},{"key":"62256","doi-asserted-by":"crossref","unstructured":"Feng Q, Wang H, Ng HH. Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain. Curr Biol. 2002; 12(12):1052-1058.","DOI":"10.1016\/S0960-9822(02)00901-6"},{"key":"62257","doi-asserted-by":"crossref","unstructured":"Asangani IA, Ateeq B, Cao Q. Characterization of the EZH2-NSD histone methyltransferase regulatory axis in cancer. Mol Cell. 2013; 49(1):80-93.","DOI":"10.1016\/j.molcel.2012.10.008"},{"key":"62258","doi-asserted-by":"crossref","unstructured":"Gulati N, B\u00e9guelin W, Giulino-Roth L. Enhancer of zeste homolog 2 (EZH2) inhibitors. Leuk Lymphoma. 2018; 59(7):1574-1585.","DOI":"10.1080\/10428194.2018.1430795"},{"key":"62259","doi-asserted-by":"crossref","unstructured":"Chong PSY, Chooi JY, Lim JSL, Toh SHM, Tan TZ, Chng WJ. SMARCA2 is a novel interactor of NSD2 and regulates prometastatic PTP4A3 through chromatin remodeling in t(4;14) multiple myeloma. Cancer Res. 2021; 81(9):2332-2344.","DOI":"10.1158\/0008-5472.CAN-20-2946"},{"key":"62260","doi-asserted-by":"crossref","unstructured":"Bohnhorst J, Rasmussen T, Moen S. Toll-like receptors mediate proliferation and survival of multiple myeloma cells. Leukemia. 2006; 20(6):1138-1144.","DOI":"10.1038\/sj.leu.2404225"},{"key":"62261","doi-asserted-by":"crossref","unstructured":"Page TH, Urbaniak AM, Espirito Santo AI. Bruton\u2019s tyrosine kinase regulates TLR7\/8-induced TNF transcription via nuclear factor-kB recruitment. Biochem Biophys Res Commun. 2018; 499(2):260-266.","DOI":"10.1016\/j.bbrc.2018.03.140"},{"key":"62262","doi-asserted-by":"crossref","unstructured":"Shinners NP, Carlesso G, Castro I. Bruton\u2019s tyrosine kinase mediates NF-kB activation and B cell survival by B cell-activating factor receptor of the TNF-R family. J Immunol. 2007; 179(6):6369.","DOI":"10.4049\/jimmunol.179.9.6369-a"},{"key":"62263","doi-asserted-by":"crossref","unstructured":"Viatour P, Merville MP, Bours V, Chariot A. Phosphorylation of NF-kappaB and IkappaB proteins: implications in cancer and inflammation. Trends Biochem Sci. 2005; 30(1):43-52.","DOI":"10.1016\/j.tibs.2004.11.009"},{"key":"62264","doi-asserted-by":"crossref","unstructured":"Weber AN, Bittner Z, Liu X, Dang T-M, Radsak MP, Brunner C. Bruton\u2019s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017; 8:1454.","DOI":"10.3389\/fimmu.2017.01454"},{"key":"62265","doi-asserted-by":"crossref","unstructured":"Wang ML, Rule S, Martin P. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369(6):507-516.","DOI":"10.1056\/NEJMoa1306220"},{"key":"62266","doi-asserted-by":"crossref","unstructured":"Rushworth SA, Bowles KM, Barrera LN. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kB. Cell Signal. 2013; 25(1):106-112.","DOI":"10.1016\/j.cellsig.2012.09.008"},{"key":"62267","doi-asserted-by":"crossref","unstructured":"Ma J, Gong W, Liu S. Ibrutinib targets microRNA-21 in multiple myeloma cells by inhibiting NF-kB and STAT3. Tumour Biol. 2018; 40(1):1010428317731369.","DOI":"10.1177\/1010428317731369"},{"key":"62268","doi-asserted-by":"crossref","unstructured":"Murray MY, Zaitseva L, Auger MJ. Ibrutinib inhibits BTK-driven NF-kB p65 activity to overcome bortezomib-resistance in multiple myeloma. Cell Cycle. 2015; 14(14):2367-2375.","DOI":"10.1080\/15384101.2014.998067"},{"key":"62269","doi-asserted-by":"crossref","unstructured":"Fischle W, Wang YM, Allis CD. Histone and chromatin cross-talk. Curr Opin Cell Biol. 2003; 15(2):172-183.","DOI":"10.1016\/S0955-0674(03)00013-9"},{"key":"62270","doi-asserted-by":"crossref","unstructured":"Lee JS, Smith E, Shilatifard A. The language of histone crosstalk. Cell. 2010; 142(5):682-685.","DOI":"10.1016\/j.cell.2010.08.011"},{"key":"62271","doi-asserted-by":"crossref","unstructured":"Kim JY, Kee HJ, Choe NW. Multiple-myeloma-related WHSC1\/NSD isoform RE-IIBP is a histone methyltransferase with transcriptional repression activity. Mol Cell Biol. 2008; 28(6):2023-2034.","DOI":"10.1128\/MCB.02130-07"},{"key":"62272","doi-asserted-by":"crossref","unstructured":"Woo Park J, Kim KB, Kim JY, Chae YC, Jeong OS, Seo SB. RE-IIBP methylates H3K79 and induces MEIS1-mediated apoptosis via H2BK120 ubiquitination by RNF20. Sci Rep. 2015; 5:12485.","DOI":"10.1038\/srep12485"},{"key":"62273","doi-asserted-by":"crossref","unstructured":"Voigt P, Tee WW, Reinberg D. A double take on bivalent promoters. Genes Dev. 2013; 27(12):1318-1338.","DOI":"10.1101\/gad.219626.113"},{"key":"62274","doi-asserted-by":"crossref","unstructured":"Wang ZL, Li B, Luo YX. Comprehensive genomic characterization of RNA-binding proteins across human cancers. Cell Rep. 2018; 22(1):286-298.","DOI":"10.1016\/j.celrep.2017.12.035"},{"key":"62275","doi-asserted-by":"crossref","unstructured":"Qin H, Ni H, Liu Y. RNA-binding proteins in tumor progression. J Hematol Oncol. 2020; 13(1):90.","DOI":"10.1186\/s13045-020-00927-w"},{"key":"62276","doi-asserted-by":"crossref","unstructured":"Hendriks RW, Yuvaraj S, Kil LP. Targeting Bruton\u2019s tyrosine kinase in B cell malignancies. Nat Rev Cancer. 2014; 14(4):219-232.","DOI":"10.1038\/nrc3702"},{"key":"62277","doi-asserted-by":"crossref","unstructured":"Chong PSY, Zhou J, Lim JSL. IL6 promotes a STAT3-PRL3 feedforward loop via SHP2 repression in multiple myeloma. Cancer Res. 2019; 79(18):4679-4688.","DOI":"10.1158\/0008-5472.CAN-19-0343"},{"key":"62278","doi-asserted-by":"crossref","unstructured":"Chong PSY, Chng WJ, de Mel S. STAT3: a promising therapeutic target in multiple myeloma. Cancers (Basel). 2019; 11(5):731.","DOI":"10.3390\/cancers11050731"},{"key":"62279","doi-asserted-by":"crossref","unstructured":"Harmer D, Falank C, Reagan MR. Interleukin-6 interweaves the bone marrow microenvironment, bone loss, and multiple myeloma. Front Endocrinol (Lausanne). 2019; 9:788.","DOI":"10.3389\/fendo.2018.00788"},{"key":"62280","doi-asserted-by":"crossref","unstructured":"Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009; 4(1):44-57.","DOI":"10.1038\/nprot.2008.211"},{"key":"62281","doi-asserted-by":"crossref","unstructured":"Schmidt EK, Clavarino G, Ceppi M, Pierre P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat Methods. 2009; 6(4):275-277.","DOI":"10.1038\/nmeth.1314"},{"key":"62282","doi-asserted-by":"crossref","unstructured":"Rahim AB, Vardy LA. Analysis of mRNA translation rate in mouse embryonic stem cells. Methods Mol Biol. 2016; 1341:143-155.","DOI":"10.1007\/7651_2015_233"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283467\/76397","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283467\/77069","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11382\/76397","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:27Z","timestamp":1794045927000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283467"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283467","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,21]]}}}